Eli Lilly Shares Decline After FDA Delays Decision on Oral Weight-Loss Pill

The U.S. Food and Drug Administration (FDA) delayed its decision on Eli Lilly’s new oral weight-loss pill. The agency set a new target date of April 10, 2026.

The decision was previously expected by late March. This review was being conducted under the FDA’s fast-track program.

Following the announcement, Eli Lilly’s shares declined in pre-market trading. The stock fell by approximately 0.9%.

The market reaction highlights investor sensitivity to potential postponements for key products. This delay introduces short-term uncertainty around the launch timeline for the company’s highly-watched obesity treatment pipeline.